<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82873">
  <stage>Registered</stage>
  <submitdate>4/06/2008</submitdate>
  <approvaldate>21/11/2008</approvaldate>
  <actrnumber>ACTRN12608000592347</actrnumber>
  <trial_identification>
    <studytitle>A Study to Investigate the Effects of Oxygen in Obesity Hypoventilation Syndrome</studytitle>
    <scientifictitle>A Randomised, Double-Blind, Cross-Over Study to Investigate the Effects of Hyperoxia on Carbon Dioxide Levels and Ventilation In Patients with Obesity Hypoventilation Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obesity Hypoventialtion Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects will be exposed to 2 interventions:
1. Inhaled 100% oxygen via a face mask for 20 minutes
2. Inhaled 21% oxygen via an identical facemask for 20 minutes.  
3. There will be a wash out phase of at least 24 hours between the 2 interventions.
4. The two gases will be administered via douglas bags filled by 21% and 100% oxygen cylinders by a third party</interventions>
    <comparator>21% oxygen inhaled via a face mask for 20 minutes</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in PaCO2 from baseline measured by a transcutaneous carbon dioxide device attached to the earlobe.</outcome>
      <timepoint>20  minutes</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in minute ventilation measured by gas flow through an electronic pneumotachygraph attached to the mouthpiece of the facemask</outcome>
      <timepoint>20 minutes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in dead space to tidal volume ratio. Measured by calculation: a combination of PaCO2 from the transcutaneous carbon dioxide device and mixed expired carbon dioxide measured by an electronic sensor on the mouthpiece of the face mask</outcome>
      <timepoint>20 minutes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A change in PaCO2 from baseline of greater then 4mmHg measured by transcutaneous carbon dioxide device</outcome>
      <timepoint>20 minutes</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with a new diagnosis of Obesity Hypoventilation Syndrome:
1. Body mass index (BMI) &gt;30kg/m2, 
2. Daytime hypercapnia (pCO2 &gt;45mmHg)</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Diagnosis of chronic airflow obstruction: post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) to Forced Vital Capacity (FVC) ratio &lt;0.7 and Forced Expiratory Volume in 1 second (FEV1) &lt;80% predicted and &gt; 10 pack year smoking history

2. Patients already receiving  treatment  with Continuous Positive Airway Pressure (CPAP) or non-invasive positive pressure ventilation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation involved contacting the holder of the allocation schedule who was based at a central administration site.</concealment>
    <sequence>Computer generated randomisation block</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Medical Research Institute of New Zealand</primarysponsorname>
    <primarysponsoraddress>Medical Research Institute of New Zealand
99 The Terrace
Wellington 6143</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Regional Ethics Committee</ethicname>
      <ethicaddress>Level 2 
1 - 3 The Terrace
PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>29/04/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Meme Wijesinghe</name>
      <address>Medical Research Institute of New Zealand
99 The Terrace
Wellington 6143</address>
      <phone>+64 21 024 777 30</phone>
      <fax />
      <email>meme.wijesinghe@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Meme Wijesinghe</name>
      <address>Medical Research Institute of New Zealand
99 The Terrace
Wellington 6143</address>
      <phone>+64 21 024 777 30</phone>
      <fax />
      <email>meme.wijesinghe@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tanya Baker</name>
      <address>Medical Research Institute of New Zealand
99 The Terrace
Wellington 6143</address>
      <phone />
      <fax />
      <email>tanya.baker@mrinz.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>